SFA Therapeutics is a clinical stage start-up biotech company developing compounds discovered in human microbiome. This patented and proprietary platform is based on immuno-modulation of inflammatory factors derived from human gut microbiome. The technology is licensed from and supported by research at Temple University in Philadelphia. These products are a unique native immunotherapy platform with activity currently being investigated in cancer, liver, and auto-immune disease.